Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.

You may also be interested in...

Collaborations Continue To Be Key For Opdivo’s Development

Deals with a wide range of companies and academic institutions are exploring nivolumab’s horizons in many solid and hematological malignancies.

Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy

The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.

BMS Taps Emory For Clinical Trials In Oncology, Other Areas

Bristol-Myers Squibb forms an alliance with Emory University to conduct mid- and late-stage trials in oncology, metabolics, hepatitis C, and immunoscience using BMS compounds.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts